159 related articles for article (PubMed ID: 30767873)
1. Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain.
Callejas-Moraga EL; Guillén-Del-Castillo A; Marín-Sánchez AM; Roca-Herrera M; Balada E; Tolosa-Vilella C; Fonollosa-Pla V; Simeón-Aznar CP
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):41-48. PubMed ID: 30767873
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.
Nikpour M; Hissaria P; Byron J; Sahhar J; Micallef M; Paspaliaris W; Roddy J; Nash P; Sturgess A; Proudman S; Stevens W
Arthritis Res Ther; 2011; 13(6):R211. PubMed ID: 22189167
[TBL] [Abstract][Full Text] [Related]
3. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
4. Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.
Ceribelli A; Krzyszczak ME; Li Y; Ross SJ; Chan JY; Chan EK; Burlingame RW; Webb TT; Bubb MR; Sobel ES; Reeves WH; Satoh M
Arthritis Res Ther; 2011 Jul; 13(4):R119. PubMed ID: 21781293
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies.
Hamaguchi Y; Kodera M; Matsushita T; Hasegawa M; Inaba Y; Usuda T; Kuwana M; Takehara K; Fujimoto M
Arthritis Rheumatol; 2015 Apr; 67(4):1045-52. PubMed ID: 25512203
[TBL] [Abstract][Full Text] [Related]
6. Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.
Motegi S; Toki S; Yamada K; Uchiyama A; Ishikawa O
J Dermatol; 2015 Feb; 42(2):189-92. PubMed ID: 25483258
[TBL] [Abstract][Full Text] [Related]
7. Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort.
Hoffmann-Vold AM; Midtvedt Ø; Tennøe AH; Garen T; Lund MB; Aaløkken TM; Andreassen AK; Elhage F; Brunborg C; Taraldsrud E; Molberg Ø
J Rheumatol; 2017 Apr; 44(4):459-465. PubMed ID: 28089974
[TBL] [Abstract][Full Text] [Related]
8. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
[TBL] [Abstract][Full Text] [Related]
9. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
[TBL] [Abstract][Full Text] [Related]
10. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study.
Meyer O; De Chaisemartin L; Nicaise-Roland P; Cabane J; Tubach F; Dieude P; Hayem G; Palazzo E; Chollet-Martin S; Kahan A; Allanore Y
J Rheumatol; 2010 Jan; 37(1):125-30. PubMed ID: 19918031
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay.
Satoh T; Ishikawa O; Ihn H; Endo H; Kawaguchi Y; Sasaki T; Goto D; Takahashi K; Takahashi H; Misaki Y; Mimori T; Muro Y; Yazawa N; Sato S; Takehara K; Kuwana M
Rheumatology (Oxford); 2009 Dec; 48(12):1570-4. PubMed ID: 19808694
[TBL] [Abstract][Full Text] [Related]
12. An analysis of the relationship between autoantibodies and clinical findings in patients with systemic sclerosis.
Yayla ME; İlgen U; Düzgün N
Turk J Med Sci; 2018 Feb; 48(1):10-15. PubMed ID: 29479936
[TBL] [Abstract][Full Text] [Related]
13. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.
Moinzadeh P; Fonseca C; Hellmich M; Shah AA; Chighizola C; Denton CP; Ong VH
Arthritis Res Ther; 2014 Feb; 16(1):R53. PubMed ID: 24524733
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA.
Santiago M; Baron M; Hudson M; Burlingame RW; Fritzler MJ
J Rheumatol; 2007 Jul; 34(7):1528-34. PubMed ID: 17610318
[TBL] [Abstract][Full Text] [Related]
15. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor.
Hesselstrand R; Scheja A; Wuttge DM
Scand J Rheumatol; 2012 Feb; 41(1):39-43. PubMed ID: 22044051
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Future Scleroderma Renal Crisis at Systemic Sclerosis Diagnosis.
Gordon SM; Stitt RS; Nee R; Bailey WT; Little DJ; Knight KR; Hughes JB; Edison JD; Olson SW
J Rheumatol; 2019 Jan; 46(1):85-92. PubMed ID: 30008456
[TBL] [Abstract][Full Text] [Related]
17. Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.
Faucher B; Stein P; Granel B; Weiller PJ; Disdier P; Serratrice J; Harlé JR; Durand JM; Frances Y; Guis S; Pham T; Bardin N; Sanmarco M
Eur J Intern Med; 2010 Apr; 21(2):114-7. PubMed ID: 20206882
[TBL] [Abstract][Full Text] [Related]
18. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis.
Kuwana M; Okano Y; Pandey JP; Silver RM; Fertig N; Medsger TA
Arthritis Rheum; 2005 Aug; 52(8):2425-32. PubMed ID: 16052583
[TBL] [Abstract][Full Text] [Related]
19. Analysis of anti-RNA polymerase III antibodies in Chinese Han systemic sclerosis patients.
Liu C; Hou Y; Xu D; Li L; Zhang Y; Cheng L; Yan S; Zhang F; Li Y
Clin Rheumatol; 2020 Apr; 39(4):1191-1197. PubMed ID: 31858335
[TBL] [Abstract][Full Text] [Related]
20. Serologic profile and mortality rates of scleroderma renal crisis in Italy.
Codullo V; Cavazzana I; Bonino C; Alpini C; Cavagna L; Cozzi F; Del Papa N; Franceschini F; Guiducci S; Morozzi G; Ruffatti A; Ferri C; Giacomelli R; Matucci-Cerinic M; Valentini G; Montecucco C
J Rheumatol; 2009 Jul; 36(7):1464-9. PubMed ID: 19487262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
